AM-36

• Description:

  AM-36 is a neuroprotective agent with combined antioxidant and sodium channel blocking actions. AM-36 can inhibit cell apoptosis and ROS prodiction. AM-36 can reduce neuronal damage and DA release after middle cerebral artery occlusion in rats. AM-36 can be used for the researches of inflammation and neurological disease, such as stroke[1][2][3].

• UNSPSC:

  12352005

• Target:

  Apoptosis; Reactive Oxygen Species (ROS) ; Sodium Channel

• Related Pathways:

  Apoptosis; Immunology/Inflammation; Membrane Transporter/Ion Channel; Metabolic Enzyme/Protease; NF-κB

• Applications:

  COVID-19-immunoregulation

• Field of Research:

  Inflammation/Immunology; Neurological Disease

• Smiles:

  ClC1=CC=C(C(CN2CCN(CC2)CC3=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C3)O)C=C1

• Molecular Formula:

  C27H39ClN2O2

• Molecular Weight:

  459.06

• References & Citations:

  [1]Callaway JK, et al. Delayed treatment with AM-36, a novel neuroprotective agent, reduces neuronal damage after endothelin-1-induced middle cerebral artery occlusion in conscious rats. Stroke. 1999 Dec;30 (12) :2704-12; discussion 2712.|[2]Callaway JK, et al. Incorporation of sodium channel blocking and free radical scavenging activities into a single drug, AM-36, results in profound inhibition of neuronal apoptosis. Br J Pharmacol. 2001 Apr;132 (8) :1691-8.|[3]Callaway JK, et al. AM-36, a novel neuroprotective agent, profoundly reduces reactive oxygen species formation and dopamine release in the striatum of conscious rats after endothelin-1-induced middle cerebral artery occlusion. Neuropharmacology. 2003 May;44 (6) :787-800.

• Shipping Conditions:

  Room temperature

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• CAS Number:

  [199467-52-2]